Entries by circlek

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma. Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., […]

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH

Oxfordshire, UK, 4 December 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of […]

Karus Therapeutics features in Biology Impacting Lives programme

Oxfordshire, UK, 11 October 2019 – Karus Therapeutics, a clinical-stage biopharmaceutical company developing precision medicines for cancer, was featured in the Biology Impacting Lives programme for its work towards developing precision medicines to target bile duct cancer. The programme from ITN Productions in partnership with the Royal Society of Biology features key industry interviews and […]

Karus Therapeutics Appoints Dr Stephen Shuttleworth as Chairman of Scientific Advisory Board

ANNOUNCEMENT Oxfordshire, UK, 17 September 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced that Dr Stephen Shuttleworth will become Chairman of its Scientific Advisory Board with immediate effect. After almost 12 years with Karus, the Company’s Founding Scientist and CSO (and latterly joint COO/CSO) and Executive […]

Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer

Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer (CMO) with immediate effect. Dr McElwaine-Johnn is a Physician with over 25 years’ experience in drug development, most recently as CMO at cancer gene […]

2018 Operational Update

Tim Edwards appointed as Executive Chairman KA2237 and KA2507 – innovative, molecular-targeted anti-cancer therapeutics – progressing in Phase I clinical trials for the treatment of cancer, with clinical responses confirmed for KA2237 in patients with refractory B-cell lymphomas Research and development activities on a novel, differentiated HDAC6 inhibitor series progressing well, with preclinical development candidate […]